Defactinib (VS-6063) Combined With VS-6766 in Patients With Metastatic Uveal Melanoma

Learn more about:
Related Clinical Trial
Prospective Registration Of Patient Data and Quality of Life in Eye Melanoma Patients Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma) The Role of Genetic Mutations and of Circulating mRNAs in Uveal Melanoma A Study of Concurrent Stereotactic Body Radiotherapy With Ipi and Nivo in Metastatic Uveal Melanoma Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma Managed Access Program Supporting Patient Access to Tebentafusp Efficacy of Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome A Study of APG-115 in Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors Early Integration of Supportive Care Into Standard Oncology Care for Metastatic Uveal Melanoma Patients Defactinib (VS-6063) Combined With VS-6766 in Patients With Metastatic Uveal Melanoma Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma A Prospective Natural History Study in Uveal Melanoma Uveal Melanoma and Brachytheraphy: Long-term Outcomes. A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas Study to Evaluate the Safety of IMM-01 in Patients With Advanced Solid Tumours Isolated Hepatic Perfusion in Combination With Ipilimumab and Nivolumab in Patients With Uveal Melanoma Metastases Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors Follow-up of Patients With Uveal Melanoma Adapted to the Risk of Relapse (SALOME) Phase 2 Trial of AU-011 Via Suprachoroidal Administration With a Dose Escalation and Randomized, Masked Dose Expansion Designed to Evaluate Safety and Efficacy of AU-011 in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery A Study of PLX2853 in Advanced Malignancies. Combined PET/CT Imaging for the Early Detection of Ocular Melanoma Metastasis Compared to CT Scanning Alone A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001) TTT Versus TTT and Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N) Genetic Predictors of Efficiency and Safety of ICIs in Patients With Different Malignancies (ICIPRESIST-0519) Treatment Of Radiation Retinopathy Trial Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin Study in Subjects With Small Primary Choroidal Melanoma Study Multicentre Evaluating the Effectiveness and Toxicity Sorafenib (Nexavar®) in Adult Patients With Uveal Melanoma and Metastatic Dissemination Trial of AEB071 in Combination With BYL719 in Patients With Melanoma Halt Growth of Liver Tumors From Uveal Melanoma With Closure of Liver Artery Following Injection of GM-CSF Vorinostat in Treating Patients With Metastatic Melanoma of the Eye Radiation Therapy in Preventing Liver Metastases in Patients With Uveal Melanoma Who HaveMonosomy 3 or DecisionDx Class 2 Disease and Are More Likely to Develop Liver Metastases 5 Year Registry Study to Track Clinical Application of DecisionDx-UM Assay Results and Associated Patient Outcomes Hypofractionated Stereotactic Linear Accelerator Radiotherapy of Uveal Melanoma Study Evaluating Single and Repeated Intravitreal Doses of ICON-1 in Patients With Uveal Melanoma Pembrolizumab in Treating Patients With Advanced Uveal Melanoma Vascular Response to Brachytherapy Using Functional OCT Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma SIR-Spheres® 90Y Microspheres Treatment of Uveal Melanoma Metastasized to Liver Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma Endoresection of the Tumor Scar or Transpupillary Thermotherapy for the Treatment of Large Uveal Melanomas (Endoresection-Laser) Durvalumab (MEDI4736) Plus Cediranib in Patients With Metastatic Uveal Melanoma A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma Study of AntiCTLA4 in Patients With Unresectable or Metastatic Uveal Melanoma Tilting of Radioactive Plaques After Initial Accurate Placement for Treatment of Uveal Melanoma A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma CAVATAK® and Ipilimumab in Uveal Melanoma Metastatic to the Liver (VLA-024 CLEVER) Comparison Between Fotemustin to Intensive Surveillance in Patients With High Risk Uveal Melanoma Dendritic Cells Plus Autologous Tumor RNA in Uveal Melanoma Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma New Biopsy Technique for Uveal Melanoma Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT) Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients Influence of Oral Treatment With Citicoline for the Prevention of Radiation Optic Neuropathy in Patients Treated for Uveal Melanomas With Proton Beam Therapy Intermittent Selumetinib for Uveal Melanoma Transarterial Radioembolisation in Comparison to Transarterial Chemoembolisation in Uveal Melanoma Liver Metastasis A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma. Evaluation Interest of the Circulating Tumor DNA Dosage in Patient With Hepatic Metastatic Uveal Melanoma Candidate to Complete Resection (ct DNA R0) Messenger Ribonucleic Acid (mRNA) Transfected Dendritic Cell Vaccination in High Risk Uveal Melanoma Patients Study of the Activity of PD-1 Inhibitors in Metastatic Uveal Melanoma A Study of Sorafenib in Patients With Chemonaive Metastatic Uveal Melanoma Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal Melanoma Vorinostat in Patients With Class 2 High Risk Uveal Melanoma Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases A Phase II Study of BVD-523 in Metastatic Uveal Melanoma Assessing the Clinical Effectiveness of Serum Biomarkers in the Diagnosis of Metastatic Uveal Melanoma Treatment With Intravitreal Avastin for Large Uveal Melanomas

Brief Title

Defactinib and VS-6766 for the Treatment of Patients With Metastatic Uveal Melanoma

Official Title

A Phase II Trial of Defactinib (VS-6063) Combined With VS-6766 (CH5126766) in Patients With Metastatic Uveal Melanoma

Brief Summary

      This phase II trial studies the effect of combining defactinib and VS-6766 in treating
      patients with uveal melanoma that has spread to other places in the body (metastatic). The
      way cells communicate with one another (different cell signaling pathways) are overactive in
      uveal melanoma tumor cells. Giving defactinib together with VS-6766 may block pathways that
      are important for the growth of uveal melanoma cells, and may result in shrinkage or
      stabilization of the cancer and prolonged time to disease progression and survival.

Detailed Description


      I. To investigate the potential efficacy of the combination of defactinib hydrochloride
      (defactinib [VS-6063]) and Raf/MEK serine/threonine kinase inhibitor RO5126766 (VS-6766) in
      patients with metastatic uveal melanoma.


      I. To assess the effectiveness of defactinib in combination with VS-6766 in patients with
      metastatic uveal melanoma (MUM).

      II. To assess the safety and toxicity profile of the combination of defactinib and VS6766.


      I. To study the pharmacodynamic profile of defactinib in combination with VS-6766 in
      pre-treatment, on-treatment, and post-treatment tumor biopsies.

      II. To investigate mechanisms of resistance to the combination of defactinib and VS-6766.

      III. To investigate the potential efficacy of circulating cell free deoxyribonucleic acid
      (DNA) for prediction/monitoring.


      Patients receive defactinib orally (PO) twice daily (BID) and VS-6766 PO twice a week (BIW)
      (Monday and Thursday or Tuesday and Friday) for 3 weeks in every cycle. Cycles repeat every
      28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed every 3 months until death or up
      to 2 years after the last patient is enrolled.

Study Phase

Phase 2

Study Type


Primary Outcome

Best overall response

Secondary Outcome

 Progression-free Survival (PFS)


Metastatic Uveal Melanoma


Defactinib Hydrochloride

Study Arms / Comparison Groups

 Treatment (defactinib, VS-6766)
Description:  Patients receive defactinib PO BID and VS-6766 PO BIW (Monday and Thursday or Tuesday and Friday) for 3 weeks in every cycle. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

January 26, 2021

Completion Date

July 2024

Primary Completion Date

October 2023

Eligibility Criteria

        Inclusion Criteria:

          1. Histologically confirmed metastatic uveal melanoma.

          2. Predicted life expectancy of at least 12 weeks.

          3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

          4. Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST)
             1.1 based on spiral computed tomography (CT) or magnetic resonance imaging (MRI) scan,
             all radiology studies must be performed within 28 days prior to registration.

          5. Corrected QT interval (QTc) < 470 ms (as calculated by the Fridericia correction
             formula, averaged over 3 electrocardiograms [ECGs])

          6. Hematological and biochemical indices within the ranges shown below. These
             measurements must be performed within two weeks (Day -14 to Day 1) before the patient
             goes on the trial.

             Hemoglobin (Hb) >= 9.0 g/dL Absolute neutrophil count (ANC) >= 1.5 x 10^9/L Platelet
             count >= 100 x 10^9/L Serum bilirubin =< 1.5 x upper limit of normal (ULN) Albumin >=
             3.0 mg/dL Creatine phosphokinase (CPK) =< 2.5 x ULN Alanine aminotransferase (ALT)
             and/or aspartate aminotransferase (AST) =< 2.5 x ULN unless raised due to tumor in
             which case up to 5 x ULN is permissible Calculated creatinine clearance >= 45 mL/min
             by the Cockcroft-Gault formula International normalized ratio (INR) =< 1.5 in absence
             of anticoagulation or therapeutic levels in presence of anticoagulation Partial
             thromboplastin time (PTT) =< 1.5 x ULN in absence of anticoagulation or therapeutic
             levels in presence of anticoagulation

          7. Patients with adequate cardiac function (left ventricular ejection fraction >= 50%) by
             echocardiography or multigated acquisition scan (MUGA) scan

          8. No active retinopathy or retinal vein occlusion confirmed by full ophthalmological
             exam in the eyet unaffected by uveal melanoma

          9. Adequate recovery from toxicities related to prior treatments to at least grade 1 by
             Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Exceptions include
             alopecia and peripheral neuropathy grade =< 2. Subjects with other toxicities that are
             stable on supportive therapy may be allowed to participate with prior approval by the

         10. Aged 18 years or over

         11. Females with reproductive potential and their male partners agree to use highly
             effective method of contraceptive (per Clinical Trial Facilitation Group [CFTG]
             recommendations during the trial and for 3 months following the last dose of study

         12. Written (signed and dated) informed consent and be capable of cooperating with
             treatment and follow-up

         13. Absence of any psychological, familial, sociological or geographical condition
             potentially hampering compliance with the study protocol and follow-up schedule

        Exclusion Criteria:

          1. Radiotherapy (except for palliative reasons), endocrine therapy, biological therapy,
             immunotherapy or chemotherapy during the previous four weeks (six weeks for
             nitrosoureas, Mitomycin-C) before treatment.

          2. Ongoing toxic manifestations of previous treatments. Exceptions to this are alopecia
             or certain Grade 1 toxicities, which in the opinion of the Investigator and the DDU
             should not exclude the patient.

          3. Known untreated or active central nervous system (CNS) metastases (progressing or
             requiring corticosteroids for symptomatic control). Patients with a history of treated
             CNS metastases are eligible, provided they meet all of the following criteria:

               -  Evaluable or measurable disease outside the CNS is present.

               -  Radiographic demonstration of improvement upon the completion of CNS- directed
                  therapy and no evidence of interim progression between the completion of CNS-
                  directed therapy and the baseline disease assessment for at least 28 days.

          4. Gilbert syndrome diagnosed with elevated indirect (unconjugated) bilirubin ( >1.2
             mg/dl) at least two occasions with normal direct bilirubin in the absence of hemolysis
             or structural liver damage.

          5. Ability to become pregnant (or already pregnant or lactating). However, those female
             patients who have a negative serum or urine pregnancy test before enrollment and agree
             to use two medically approved forms of contraception (oral, injected or implanted
             hormonal contraception and condom, have an intra-uterine device and condom, diaphragm
             with spermicidal gel and condom) from time of consent, during the trial and for six
             months afterwards are considered eligible.

          6. Male patients with partners of child-bearing potential (unless they agree to take
             measures not to father children by using one form of medically approved contraception
             [condom plus spermicide] during the trial and for six months afterwards). Men with
             pregnant or lactating partners should be advised to use barrier method contraception
             (for example, condom plus spermicidal gel) to prevent exposure to the fetus or

          7. Major surgery within 4 weeks prior to entry to the study (excluding placement of
             vascular access), or minor surgery within 2 weeks of entry into the study and from
             which the patient has not yet recovered.

          8. Treatment with warfarin. Patients on warfarin for DVT/PE can be converted to
             low-molecular-weight heparin (LMWH).

          9. Acute or chronic pancreatitis.

         10. At high medical risk because of non-malignant systemic disease including active
             uncontrolled infection.

         11. Known to be serologically positive for hepatitis B, hepatitis C or human
             immunodeficiency virus (HIV).

         12. Patients with the inability to swallow oral medications or impaired gastrointestinal
             absorption due to gastrectomy or active inflammatory bowel disease.

         13. History of abdominal fistula, gastro-intestinal perforation, or diverticulitis.

         14. Patients with history of symptomatic cholelithiasis or cholecystitis within six months
             before enrollment.

         15. Concurrent ocular disorders in the eye unaffected by uveal melanoma:

               1. Patients with history of retinal vein occlusion (RVO), predisposing factors for
                  RVO, including uncontrolled hypertension, uncontrolled diabetes

               2. Patients with history of retinal pathology or evidence of visible retinal
                  pathology that is considered a risk factor for RVO, intraocular pressure > 21 mm
                  Hg as measured by tonometry, or other significant ocular pathology, such as
                  anatomical abnormalities that increase the risk for RVO.

               3. Patients with a history of corneal erosion (instability of corneal epithelium),
                  corneal degeneration, active or recurrent keratitis, and other forms of serious
                  ocular surface inflammatory conditions.

         16. Concurrent congestive heart failure, prior history of class III/ IV cardiac disease
             (New York Heart Association [NYHA]), myocardial infarction within the last 6 months,
             unstable arrhythmias, unstable angina or severe obstructive pulmonary disease.

         17. Patients exposed to strong CYP3A4 and strong CYP2C9 inhibitors within 7 days prior to
             the first dose. Because the lists of these agents are constantly changing, it is
             important to regularly consult a frequently-updated list such as
   ; medical reference texts such as
             the Physicians' Desk Reference may also provide this information.

         18. Is a participant or plans to participate in another interventional clinical trial,
             whilst taking part in this Phase II study of VS-6766 in combination with VS-

        6063. Participation in an observational trial would be acceptable. 19. Patients with a
        history of hypersensitivity to any of the inactive ingredients
        (hydroxypropylmethylcellulose, mannitol, magnesium stearate) of the investigational
        product. 20. Prior corticosteroids as anti-cancer therapy within a minimum of 14 days of
        first receipt of study drugs. 21. Any other condition which in the Investigator's opinion
        would not make the patient a good candidate for the clinical trial.




18 Years - N/A

Accepts Healthy Volunteers



Takami Sato, 215-955-8874, [email protected]

Location Countries

United States

Location Countries

United States

Administrative Informations



Organization ID


Responsible Party


Study Sponsor

Thomas Jefferson University


 Verastem, Inc.

Study Sponsor

Takami Sato, Principal Investigator, Thomas Jefferson University

Verification Date

January 2022